이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Finch Therapeutics Group 대차 대조표 상태

재무 상태 기준 확인 3/6

Finch Therapeutics Group 의 총 주주 지분은 $19.0M 이고 총 부채는 $0.0, 이는 부채 대 자기자본 비율을 0% 로 가져옵니다. 총자산과 총부채는 각각 $50.1M 및 $31.1M 입니다.

주요 정보

부채 비율

US$0

부채

이자 보상 비율	n/a
현금	US$20.76m
주식	US$19.04m
총 부채	US$31.05m
총 자산	US$50.09m

최근 재무 상태 업데이트

Recent updates

Finch to cut workforce by about 37% after Takeda ends bowel disease collaboration

Sep 01

Finch to get back rights to IBD product candidates after Takeda ends collaboration

Aug 25

Finch Therapeutics GAAP EPS of -$0.48 misses by $0.07, revenue of $0.36M

Aug 11

Here's Why We're Watching Finch Therapeutics Group's (NASDAQ:FNCH) Cash Burn Situation

Mar 15

Here's Why We're Watching Finch Therapeutics Group's (NASDAQ:FNCH) Cash Burn Situation

Dec 15

We Think Finch Therapeutics Group (NASDAQ:FNCH) Needs To Drive Business Growth Carefully

Aug 28

Finch Therapeutics: Gut Instinct Says Buy

Jun 14

재무 상태 분석

단기부채: FNCH 의 단기 자산 ( $21.2M )이 단기 부채( $3.5M ).

장기 부채: FNCH 의 단기 자산( $21.2M )은 장기 부채( $27.6M ).

부채 대 자본 내역 및 분석

부채 수준: FNCH 부채가 없습니다.

부채 감소: FNCH 5년 전에 부채가 없었습니다.

대차 대조표

현금 런웨이 분석

과거에 평균적으로 적자를 기록했던 기업의 경우, 최소 1년 이상의 현금 유동성을 보유하고 있는지 평가합니다.

안정적인 현금 활주로: FNCH 현재 무료 현금 흐름을 기준으로 1년 미만의 cash runway를 보유하고 있습니다.

예측 현금 활주로: 무료 현금 흐름이 매년 0.8 %의 역사적 비율로 계속 증가할 경우 FNCH 의 현금 활주로는 1년 미만입니다.

Finch Therapeutics Group 대차 대조표 상태

재무 상태 기준 확인 3/6

주요 정보

최근 재무 상태 업데이트

Finch Therapeutics Group Receives the Delisting Letter from the Office of the General Counsel of Nasdaq Notifying the Listing Panel Determines to Delist the Company from Nasdaq

Nasdaq Listing Qualifications Department Issues an Additional Staff Determination to Finch Therapeutics Group for Continued Non-Compliance with the Market Value of Publicly Held Shares Rule

Finch Therapeutics Receives Notice from Nasdaq Regarding Non-Compliance with the Requirements of Nasdaq Listing Rule 5605(c)(2)

The Nasdaq Stock Market LLC Notifies Finch Therapeutics Regarding Company’s Status as 'Public Shell'

Finch Therapeutics Group Receives Non-Compliance Notice from Nasdaq

Finch Therapeutics Announces 1-for-30 Reverse Stock Split of Common Stock to Satisfy the Minimum Price Requirement for Continued Listing on the Nasdaq Global Select Market

Recent updates

Finch Therapeutics Group, Inc.(OTCPK:FNCH) dropped from NASDAQ Composite Index

Finch Therapeutics Group Receives the Delisting Letter from the Office of the General Counsel of Nasdaq Notifying the Listing Panel Determines to Delist the Company from Nasdaq

Nasdaq Listing Qualifications Department Issues an Additional Staff Determination to Finch Therapeutics Group for Continued Non-Compliance with the Market Value of Publicly Held Shares Rule

Finch Therapeutics Receives Notice from Nasdaq Regarding Non-Compliance with the Requirements of Nasdaq Listing Rule 5605(c)(2)

The Nasdaq Stock Market LLC Notifies Finch Therapeutics Regarding Company’s Status as 'Public Shell'

Finch Therapeutics Group Receives Non-Compliance Notice from Nasdaq

New major risk - Share price stability

Finch Therapeutics Announces 1-for-30 Reverse Stock Split of Common Stock to Satisfy the Minimum Price Requirement for Continued Listing on the Nasdaq Global Select Market

First quarter 2023 earnings released: US$1.33 loss per share (vs US$0.52 loss in 1Q 2022)

Finch Therapeutics Group, Inc. Reports Unaudited Consolidated Impairment of Long-Lived Assets for the First Quarter Ended March 31, 2023

Full year 2022 earnings: EPS and revenues miss analyst expectations

Finch Therapeutics Group, Inc. Announces Decision to Discontinue Phase 3 Trial of CP101 and Focus on Realizing the Value of Its Intellectual Property Estate and Other Assets

Finch Therapeutics Group, Inc. Announces Resignation of Joseph Vittiglio as Chief Business and Legal Officer and Secretary, Effective December 31, 2022

Price target decreased to US$12.00

Finch Therapeutics Group, Inc. Plans to Reduce its Workforce by Approximately 37%

Finch to cut workforce by about 37% after Takeda ends bowel disease collaboration

Finch to get back rights to IBD product candidates after Takeda ends collaboration

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Finch Therapeutics GAAP EPS of -$0.48 misses by $0.07, revenue of $0.36M

High number of new directors

Finch Therapeutics Group, Inc.(NasdaqGS:FNCH) dropped from Russell 2500 Value Index

Finch Therapeutics Announces Workforce Restructuring to Focus Resources on Key Development Programs

Price target decreased to US$27.67

Here's Why We're Watching Finch Therapeutics Group's (NASDAQ:FNCH) Cash Burn Situation

Finch Therapeutics Group, Inc. Pauses Enrollment in PRISM4 Its Phase 3 Clinical Trial of CP101 in Recurrent C. Difficile Infection

Finch Therapeutics Group, Inc. Announces Executive Appointments

Finch Therapeutics Group, Inc. Announces U.S. Patent and Trademark Office Grants Two New Patents for FIN-211

High number of new directors

Here's Why We're Watching Finch Therapeutics Group's (NASDAQ:FNCH) Cash Burn Situation

Third quarter 2021 earnings released: US$0.21 loss per share

We Think Finch Therapeutics Group (NASDAQ:FNCH) Needs To Drive Business Growth Carefully

Finch Therapeutics: Gut Instinct Says Buy

Key Executive recently bought US$12m worth of stock

재무 상태 분석

부채 대 자본 내역 및 분석

대차 대조표

현금 런웨이 분석

건강한 기업 발견하기